Reslizumab (CINQAIR) worked as add-on treatment for severe asthma with eosinophilia
www.pulmccm.org
Reslizumab (CINQAIR) is a humanized, anti-IL-5 biologic agent approved by FDA in March 2016 as add-on treatment for asthma with peripheral blood eosinophilia, uncontrolled by usual treatments.
Reslizumab (CINQAIR) worked as add-on treatment for severe asthma with eosinophilia
Reslizumab (CINQAIR) worked as add-on…
Reslizumab (CINQAIR) worked as add-on treatment for severe asthma with eosinophilia
Reslizumab (CINQAIR) is a humanized, anti-IL-5 biologic agent approved by FDA in March 2016 as add-on treatment for asthma with peripheral blood eosinophilia, uncontrolled by usual treatments.